“I am pleased that I have already been involved in numerous contentious proceedings in my career to date and have been able to celebrate many wins with our clients. As the chemical and life sciences sector is booming and the challenges continue to grow, it is critical for us as a team to stay on top of our game and continually expand our expertise.”
Dr. Romina Kühnle, patent attorney and partner at COHAUSZ & FLORACK
Whether in pharmaceuticals, polymer chemistry, biochemistry, food chemistry, or materials science: We cover the entire spectrum of technical issues in the field of chemistry and life sciences. The partners of COHAUSZ & FLORACK are supported by a strong team of patent attorneys, attorneys at law and paralegals. We are thus optimally positioned to meet all of our clients' needs.
Effective and affordable: opposition proceedings
One way of taking action against restrictions imposed by a competitor is by bringing opposition proceedings. The advantages:
- Opposition proceedings can be filed within the first nine months after publication of the mention of the grant of the patent.
- They are much less expensive than revocation proceedings.
- Opposition proceedings are the method of choice for a European patent in particular, as nullity proceedings do not have to be conducted in individual European countries.
The chemicals and life sciences sectors are fiercely competitive, also given the competition from generics companies. As originators, many of our clients have invested large sums of money in the research and development of their products and have a legitimate interest in selling them exclusively for the entire term of the patent. This is where we come in! We also represent our clients in highly complex and time-consuming opposition proceedings.
Supplementary protection certificates are a unique feature of the chemicals and life sciences sectors. They can be used to extend patent protection for certain drugs and plant protection products – by a maximum of five years. This always comes with additional market exclusivity for you as the patent holder. We are happy to advise you on this, too!
UPC Update - The new CMS is online
On July 8, the UPC has launched the first phase of its new CMS-rollout. Starting with limited functional scope, the new CMS is set to become fully operational in September.
G 1/23: No “Enablement” Hurdle for Prior Art Products Put on the Market – EPO Clarifies Scope of Prior Art
Enlarged Board of Appeal confirms: Commercially available products are prior art, even if they are not fully analyzable or reproducible
How the EPO addresses public prior use in clinical trials and patentability obstacles for pharmaceutical inventions
This article explores how the European Patent Office (EPO) addresses public prior use in the context of clinical trials.
IP strategies for the second funding round
As you scale, investors are looking at more than the potential of your IP, says Mathias Karlhuber. They now want to know whether it can support future growth and withstand any attacks.